a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS
NCT ID: NCT06271044
Last Updated: 2024-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
61 participants
INTERVENTIONAL
2014-10-31
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma
NCT04354324
Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma
NCT06087068
Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer
NCT01744769
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
NCT00673010
Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.
NCT06134830
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods: either to follow-up patients according to the study protocol without radioiodine treatment or to give a radioiodine treatment with a dose of 1.1 GBq according to the normal Finnish treatment protocol for papillary thyroid cancer to those patients who themselves preferred to have a normal postoperative treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RAILESS
Railess group including patients to bw followed up wihtout postoperative radioiodine treatment
No interventions assigned to this group
rairinn
THose patients receiving radioiodine treatment according to the normal treatment practice at that time
With radioiodine treatment
Postoperative radioiodine not given
With postoperative radioiodine treatment
Postoperative radioiodine given
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
With radioiodine treatment
Postoperative radioiodine not given
With postoperative radioiodine treatment
Postoperative radioiodine given
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no lymphnode metastases
Exclusion Criteria
* mutlifocal papillary cancer
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helsinki University Central Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paivi Halonen
Medical Oncologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Päivi Halonen, MD
Role: PRINCIPAL_INVESTIGATOR
Medical Oncologist
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RAILESS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.